Announcements Trials
Browse Landscape Eligibility

Clinical Trials

101,156 trials
RecentStart dateEnrollment

Phase

Phase 2 24477Phase NA 21760Phase 1 13825Phase 3 7871Phase 1/2 6890Phase 4 2171Phase EARLY_PHASE1 1557Phase 2/3 1216

Status

Completed 43544Unknown 16210Recruiting 15948Terminated 9167Active not recruiting 6495Not yet recruiting 5008Withdrawn 3377Enrolling by invitation 621Suspended 393No longer available 182Approved for marketing 87Available 83Temporarily not available 7

Sponsor Class

OTHER 69405INDUSTRY 22582NIH 4392NETWORK 2160OTHER_GOV 2077FED 231UNKNOWN 229INDIV 46

Study Type

Interventional 79772Observational 20991Expanded_access 359

Sponsor

Cancer Type

Gastrointestinal 19723Breast 12922Thoracic 10560Genitourinary 9964Lymphoid 9088Other hematologic neoplasm 8105Gynecologic 6250Head & Neck 5348CNS 5233Dermatologic 4159Tumor-Agnostic 3972Plasma cell 3330Other solid neoplasm 3226Sarcoma 3144Myeloid 2290Endocrine 1496Classical hematology 947Other 750NET 518Other neoplasm 301

Conditions

Breast Neoplasms 10998Neoplasms 8807Carcinoma, Non-Small-Cell Lung 5711Prostatic Neoplasms 5278Colorectal Neoplasms 4951Lung Neoplasms 4210Pancreatic Neoplasms 3003Multiple Myeloma 3001Neoplasm Metastasis 2954Leukemia, Myeloid, Acute 2927Carcinoma, Hepatocellular 2734Ovarian Neoplasms 2657Melanoma 2635Stomach Neoplasms 2567Lymphoma 2502Head and Neck Neoplasms 2162Recurrence 2132Precursor Cell Lymphoblastic Leukemia-Lymphoma 2069Leukemia 1992Brain Neoplasms 1971Colonic Neoplasms 1939Lymphoma, Non-Hodgkin 1894Rectal Neoplasms 1846Uterine Cervical Neoplasms 1806Glioblastoma 1699Leukemia, Lymphocytic, Chronic, B-Cell 1663Carcinoma, Renal Cell 1597Squamous Cell Carcinoma of Head and Neck 1550Lymphoma, Follicular 1526Esophageal Neoplasms 1516

Interventions

Cyclophosphamide 2681Cisplatin 2665Carboplatin 2462Radiotherapy 2370Paclitaxel 2264Gemcitabine 2128pembrolizumab 1993Docetaxel 1883Bevacizumab 1821Fluorouracil 1548Capecitabine 1532Oxaliplatin 1440Dexamethasone 1330Nivolumab 1300Doxorubicin 1260Rituximab 1249Magnetic Resonance Spectroscopy 1150Etoposide 1126Irinotecan 1038Leucovorin 1020Drug Therapy 999Cytarabine 964Pemetrexed 891fludarabine 889Specimen Handling 822Vincristine 793Lenalidomide 791Cetuximab 785Prednisone 785Trastuzumab 785

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT00045201 2026-03-18

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
60 enrolled

Adult Solid Neoplasm

NCT00070499 2026-03-18

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
406 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00099437 2026-03-18

CONFIRM

AstraZeneca

Phase 3 Active not recruiting
736 enrolled 14 charts
Breast

Breast Neoplasms

NCT00217737 2026-03-18

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
2,431 enrolled 13 charts
Gastrointestinal

Colonic Neoplasms

NCT00268385 2026-03-18

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
83 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00310180 2026-03-18

TAILORx

National Cancer Institute (NCI)

Phase 3 Active not recruiting
10,273 enrolled 14 charts
Breast

Breast Neoplasms

NCT00336063 2026-03-18

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
18 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT00392353 2026-03-18

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
135 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00569127 2026-03-18

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

National Cancer Institute (NCI)

Phase 3 Active not recruiting
427 enrolled 17 charts
EndocrineNET

Neuroendocrine Tumors

NCT00571389 2026-03-18

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

BioCytics, Inc.

Recruiting
1,500 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT00658814 2026-03-18

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
133 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00740805 2026-03-18

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
81 enrolled
Lymphoid

Ann Arbor Stage III Non-Hodgkin Lymphoma

NCT00792948 2026-03-18

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
97 enrolled 7 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00804154 2026-03-18

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
45 enrolled

Cancer Pain, Pain, Intractable

NCT00843882 2026-03-18

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00937937 2026-03-18

Dinaciclib in Treating Patients With Stage IV Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled 14 charts
Dermatologic

Melanoma

NCT00959556 2026-03-18

Study of Blood Samples in Patients With Breast Cancer

Centre Oscar Lambret

Completed
Breast

Breast Neoplasms

NCT00980460 2026-03-18

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

NCT01038778 2026-03-18

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
47 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell

NCT01051895 2026-03-18

CoHIPP

Centre hospitalier de l'Université de Montréal (CHUM)

Phase NA Active not recruiting
2,253 enrolled
Gynecologic

High Grade Cervical Intra-epithelial Neoplasia

NCT01064648 2026-03-18

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
117 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT01089101 2026-03-18

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
220 enrolled
CNS

Astrocytoma, Neurofibromatosis 1

NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
692 enrolled 11 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms

NCT01251861 2026-03-18

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
108 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT01267955 2026-03-18

Vismodegib in Treating Patients With Advanced Chondrosarcomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
45 enrolled 10 charts
Sarcoma

Chondrosarcoma, Clear Cell, Chondrosarcoma, Chondrosarcoma, Mesenchymal

NCT01272037 2026-03-18

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT01303341 2026-03-18

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled
Dermatologic

Melanoma

NCT01327781 2026-03-18

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
Breast

Breast Neoplasms

NCT01351909 2026-03-18

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled
Breast

Breast Neoplasms

NCT01364051 2026-03-18

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

National Cancer Institute (NCI)

Phase 1 Active not recruiting
19 enrolled
Dermatologic

Melanoma

NCT01375829 2026-03-18

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled

Adult Solid Neoplasm

NCT01386385 2026-03-18

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
53 enrolled 21 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT01434316 2026-03-18

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
121 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT01468896 2026-03-18

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
23 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01522976 2026-03-18

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01552356 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled

Solid Neoplasm

NCT01570998 2026-03-18

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

University of California, San Francisco

Phase NA Active not recruiting
1,259 enrolled
Breast

Breast Neoplasms

NCT01575548 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

National Cancer Institute (NCI)

Phase 3 Active not recruiting
129 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT01587352 2026-03-18

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Dermatologic

Uveal Melanoma

NCT01627041 2026-03-18

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
178 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT01647555 2026-03-18

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Centre Oscar Lambret

Completed
57 enrolled
Head & Neck

Head and Neck Neoplasms

NCT01660971 2026-03-18

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
19 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01695941 2026-03-18

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT01711554 2026-03-18

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
27 enrolled
CNS

Neuroblastoma

NCT01780064 2026-03-18

APAPI

Centre Oscar Lambret

Phase NA Terminated
128 enrolled
Breast

Breast Neoplasms

NCT01841723 2026-03-18

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT01841736 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT01861314 2026-03-18

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Active not recruiting
15 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01886872 2026-03-18

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
547 enrolled 19 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01979523 2026-03-18

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
42 enrolled 13 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡